Glenmark Life Sciences Limited
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and m… Read more
Glenmark Life Sciences Limited (GLS) - Net Assets
Latest net assets as of September 2024: ₹25.38 Billion INR
Based on the latest financial reports, Glenmark Life Sciences Limited (GLS) has net assets worth ₹25.38 Billion INR as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹30.85 Billion) and total liabilities (₹5.46 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹25.38 Billion |
| % of Total Assets | 82.29% |
| Annual Growth Rate | N/A |
| 5-Year Change | 480.62% |
| 10-Year Change | N/A |
| Growth Volatility | 130.42 |
Glenmark Life Sciences Limited - Net Assets Trend (2018–2024)
This chart illustrates how Glenmark Life Sciences Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Glenmark Life Sciences Limited (2018–2024)
The table below shows the annual net assets of Glenmark Life Sciences Limited from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-03-31 | ₹23.32 Billion | +9.08% |
| 2023-03-31 | ₹21.38 Billion | +4.08% |
| 2022-03-31 | ₹20.54 Billion | +172.91% |
| 2021-03-31 | ₹7.53 Billion | +87.39% |
| 2020-03-31 | ₹4.02 Billion | +355.82% |
| 2019-03-31 | ₹881.25 Million | +6403.65% |
| 2018-03-31 | ₹-13.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Glenmark Life Sciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1293211000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹12.92 Billion | 55.39% |
| Common Stock | ₹245.05 Million | 1.05% |
| Other Comprehensive Income | ₹110.58 Million | 0.47% |
| Other Components | ₹10.05 Billion | 43.09% |
| Total Equity | ₹23.32 Billion | 100.00% |
Glenmark Life Sciences Limited Competitors by Market Cap
The table below lists competitors of Glenmark Life Sciences Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Asseco South Eastern Europe S.A.
WAR:ASE
|
$389.34 Million |
|
Inox Wind Limited
NSE:INOXWIND
|
$389.47 Million |
|
Beijing Deep Glint Technology Co. Ltd. A
SHG:688207
|
$389.49 Million |
|
SIMPAR S.A
SA:SIMH3
|
$389.49 Million |
|
EVN Finance JSC
VN:EVF
|
$389.14 Million |
|
Prudent Corporate Advisory Services Limited
NSE:PRUDENT
|
$389.11 Million |
|
São Martinho S.A
SA:SMTO3
|
$389.11 Million |
|
StarHub Ltd
F:RYTB
|
$388.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Glenmark Life Sciences Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 21,382,070,000 to 23,323,220,000, a change of 1,941,150,000 (9.1%).
- Net income of 4,708,880,000 contributed positively to equity growth.
- Dividend payments of 2,756,860,000 reduced retained earnings.
- Other comprehensive income increased equity by 43,750,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹4.71 Billion | +20.19% |
| Dividends Paid | ₹2.76 Billion | -11.82% |
| Other Comprehensive Income | ₹43.75 Million | +0.19% |
| Other Changes | ₹-54.62 Million | -0.23% |
| Total Change | ₹- | 9.08% |
Book Value vs Market Value Analysis
This analysis compares Glenmark Life Sciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-03-31 | ₹-0.13 | ₹1100.60 | x |
| 2019-03-31 | ₹7.19 | ₹1100.60 | x |
| 2020-03-31 | ₹37.26 | ₹1100.60 | x |
| 2021-03-31 | ₹69.82 | ₹1100.60 | x |
| 2022-03-31 | ₹174.78 | ₹1100.60 | x |
| 2023-03-31 | ₹174.51 | ₹1100.60 | x |
| 2024-03-31 | ₹190.10 | ₹1100.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Glenmark Life Sciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.19%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.62%
- • Asset Turnover: 0.80x
- • Equity Multiplier: 1.22x
- Recent ROE (20.19%) is below the historical average (74.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -175.00% | 2.92x | 0.00x | ₹-2.94 Million |
| 2019 | 332.11% | 20.83% | 0.95x | 16.74x | ₹2.84 Billion |
| 2020 | 77.94% | 20.37% | 0.89x | 4.30x | ₹2.73 Billion |
| 2021 | 46.71% | 18.65% | 0.94x | 2.65x | ₹2.76 Billion |
| 2022 | 20.38% | 19.72% | 0.86x | 1.20x | ₹2.13 Billion |
| 2023 | 21.84% | 21.61% | 0.80x | 1.26x | ₹2.53 Billion |
| 2024 | 20.19% | 20.62% | 0.80x | 1.22x | ₹2.38 Billion |
Industry Comparison
This section compares Glenmark Life Sciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Glenmark Life Sciences Limited (GLS) | ₹25.38 Billion | 0.00% | 0.22x | $389.27 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |